Pancreatic Cancer — SCE Medical Oncology MCQ

Instant feedback + full explanation. One question, done properly.

HardGI CancersPancreatic CancerSCE Medical Oncology

In PRODIGE 4/ACCORD 11, median overall survival was 11.1 months with FOLFIRINOX and 6.8 months with gemcitabine. What was the absolute median-survival gain to communicate when appraising the landmark result?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: A — 4.3 months

The absolute difference is 11.1 minus 6.8, which equals 4.3 months. The other values are an arithmetic error, either arm median, or an incorrect subtraction. This is a trial-level median comparison, not an individual survival prediction.

Reference: PRODIGE 4/ACCORD 11. https://pubmed.ncbi.nlm.nih.gov/21561347/